Primary Generalized Epilepsy

Drug under Investigation:  Lamictal (Lamotrigine) extended release

Purpose of Study:  To assess the efficacy of once daily adjunctive therapy with LTG extended-release in subjects with PGTC seizures.

Inclusion Criteria:

• Is 13 years old or older
• Diagnosis of epilepsy with PGTC seizures for more than 24 weeks prior to study
• Has a documented history of PGTC seizures with or without other generalized seizure type(s) with no focal onset, and at least 1 PGTC seizure during the eight consecutive weeks prior to study
• Is currently treated with a stable regimen of one or two AED(s) for at least four weeks prior to study

Exclusion Criteria:

• Prior exposure to lamotrigine
• Exposure to investigational drug or felbamate
• Has a history of partial seizures
• Is taking three or more background AEDs chronically
• History of status epilepticus within the 24 weeks prior to study
• Is abusing alcohol and/or other substance(s)

If you qualify, all study related care is provided at no charge including:

• Study visits and study related procedures/tests
• Laboratory tests
• Study medication
• Financial compensation for time/travel expenses

Inclusion/Exclusion Criteria Must Be Met